GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (STU:2X1) » Definitions » Gross-Profit-to-Asset %

Abivax (STU:2X1) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Abivax Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Abivax's annualized Gross Profit for the quarter that ended in Dec. 2024 was €0.00 Mil. Abivax's average Total Assets over the quarter that ended in Dec. 2024 was €266.15 Mil. Therefore, Abivax's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.


Abivax Gross-Profit-to-Asset % Historical Data

The historical data trend for Abivax's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Gross-Profit-to-Asset % Chart

Abivax Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -54.92 -50.43 -54.95 - -

Abivax Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Abivax's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Abivax's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abivax's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Abivax's Gross-Profit-to-Asset % falls into.


;
;

Abivax Gross-Profit-to-Asset % Calculation

Abivax's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=0/( (327.062+205.228)/ 2 )
=0/266.145
=0.00 %

Abivax's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (327.062+205.228)/ 2 )
=0/266.145
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Abivax Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Abivax's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Abivax Business Description

Industry
Traded in Other Exchanges
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Abivax Headlines

No Headlines